10x Genomics Statistics
Total Valuation
10x Genomics has a market cap or net worth of $2.05 billion. The enterprise value is $1.62 billion.
Important Dates
The last earnings date was Thursday, November 6, 2025, after market close.
| Earnings Date | Nov 6, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
10x Genomics has 126.55 million shares outstanding. The number of shares has increased by 3.07% in one year.
| Current Share Class | 116.47M |
| Shares Outstanding | 126.55M |
| Shares Change (YoY) | +3.07% |
| Shares Change (QoQ) | +0.80% |
| Owned by Insiders (%) | 10.45% |
| Owned by Institutions (%) | 94.22% |
| Float | 111.39M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 3.05 |
| Forward PS | 3.34 |
| PB Ratio | 2.56 |
| P/TBV Ratio | 2.82 |
| P/FCF Ratio | 24.71 |
| P/OCF Ratio | 22.79 |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 2.53 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | 19.87 |
Financial Position
The company has a current ratio of 4.48, with a Debt / Equity ratio of 0.11.
| Current Ratio | 4.48 |
| Quick Ratio | 3.93 |
| Debt / Equity | 0.11 |
| Debt / EBITDA | n/a |
| Debt / FCF | 1.07 |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -10.12% and return on invested capital (ROIC) is -9.85%.
| Return on Equity (ROE) | -10.12% |
| Return on Assets (ROA) | -8.42% |
| Return on Invested Capital (ROIC) | -9.85% |
| Return on Capital Employed (ROCE) | -15.04% |
| Revenue Per Employee | $491,435 |
| Profits Per Employee | -$58,438 |
| Employee Count | 1,306 |
| Asset Turnover | 0.65 |
| Inventory Turnover | 2.56 |
Taxes
In the past 12 months, 10x Genomics has paid $3.23 million in taxes.
| Income Tax | 3.23M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +23.16% in the last 52 weeks. The beta is 2.18, so 10x Genomics's price volatility has been higher than the market average.
| Beta (5Y) | 2.18 |
| 52-Week Price Change | +23.16% |
| 50-Day Moving Average | 13.14 |
| 200-Day Moving Average | 11.53 |
| Relative Strength Index (RSI) | 64.34 |
| Average Volume (20 Days) | 3,038,972 |
Short Selling Information
The latest short interest is 15.02 million, so 11.87% of the outstanding shares have been sold short.
| Short Interest | 15.02M |
| Short Previous Month | 12.55M |
| Short % of Shares Out | 11.87% |
| Short % of Float | 13.48% |
| Short Ratio (days to cover) | 5.79 |
Income Statement
In the last 12 months, 10x Genomics had revenue of $641.81 million and -$76.32 million in losses. Loss per share was -$0.62.
| Revenue | 641.81M |
| Gross Profit | 442.49M |
| Operating Income | -132.38M |
| Pretax Income | -73.09M |
| Net Income | -76.32M |
| EBITDA | -97.50M |
| EBIT | -132.38M |
| Loss Per Share | -$0.62 |
Full Income StatementBalance Sheet
The company has $482.08 million in cash and $86.99 million in debt, giving a net cash position of $395.10 million or $3.12 per share.
| Cash & Cash Equivalents | 482.08M |
| Total Debt | 86.99M |
| Net Cash | 395.10M |
| Net Cash Per Share | $3.12 |
| Equity (Book Value) | 785.12M |
| Book Value Per Share | 6.20 |
| Working Capital | 512.50M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was $88.53 million and capital expenditures -$6.87 million, giving a free cash flow of $81.65 million.
| Operating Cash Flow | 88.53M |
| Capital Expenditures | -6.87M |
| Free Cash Flow | 81.65M |
| FCF Per Share | $0.65 |
Full Cash Flow StatementMargins
Gross margin is 68.94%, with operating and profit margins of -20.63% and -11.89%.
| Gross Margin | 68.94% |
| Operating Margin | -20.63% |
| Pretax Margin | -11.39% |
| Profit Margin | -11.89% |
| EBITDA Margin | -15.19% |
| EBIT Margin | -20.63% |
| FCF Margin | 12.72% |
Dividends & Yields
10x Genomics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -3.07% |
| Shareholder Yield | -3.07% |
| Earnings Yield | -3.78% |
| FCF Yield | 4.05% |
Dividend DetailsAnalyst Forecast
The average price target for 10x Genomics is $14.50, which is -10.66% lower than the current price. The consensus rating is "Buy".
| Price Target | $14.50 |
| Price Target Difference | -10.66% |
| Analyst Consensus | Buy |
| Analyst Count | 13 |
| Revenue Growth Forecast (5Y) | 4.20% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
10x Genomics has an Altman Z-Score of 2.6 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.6 |
| Piotroski F-Score | 3 |
